{"disease":{"id":"critical-limb-threatening-ischemia","name":"critical limb threatening ischemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05821829","title":"Endovascular Treatment of Primary Common FEmoral Artery atheroSclerotic Disease wiTh IntraVAscular Litothripsy","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"University of Pisa","has_results":false},{"nct_id":"NCT03970538","title":"PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":105,"lead_sponsor_name":"LimFlow, Inc.","has_results":true},{"nct_id":"NCT05313165","title":"PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"LimFlow, Inc.","has_results":false},{"nct_id":"NCT03124875","title":"PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"LimFlow, Inc.","has_results":true},{"nct_id":"NCT06075940","title":"Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"R3 Vascular Inc.","has_results":false},{"nct_id":"NCT06056193","title":"The SIR-POBA Bypass Trial","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Paracelsus Medical University","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}